Go Pro
NASDAQ:MLTX

MoonLake Immunotherapeutics Q1 2026 Earnings Report

MoonLake Immunotherapeutics logo
$15.62 +0.06 (+0.39%)
As of 04:00 PM Eastern

MoonLake Immunotherapeutics EPS Results

Actual EPS
-$0.98
Consensus EPS
-$0.91
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

MoonLake Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MoonLake Immunotherapeutics Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Monday, May 11, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

MoonLake Immunotherapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

MoonLake Immunotherapeutics Earnings Headlines

MoonLake Immunotherapeutics (MLTX)
What is HC Wainwright's Forecast for MLTX Q3 Earnings?
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
See More MoonLake Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

View MoonLake Immunotherapeutics Profile